Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept (Q42674268)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 2012

Language	Label	Description	Also known as
English	Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept	scientific article published on December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept (English)

1 reference

Europe PubMed Central

4 November 2017

traumatic brain injury

0 references

author name string

Edward Tobinick

1

1 reference

Europe PubMed Central

4 November 2017

Nancy M Kim

2

1 reference

Europe PubMed Central

4 November 2017

Gary Reyzin

3

1 reference

Europe PubMed Central

4 November 2017

Helen Rodriguez-Romanacce

4

1 reference

Europe PubMed Central

4 November 2017

Venita DePuy

5

1 reference

Europe PubMed Central

4 November 2017

publication date

1 December 2012

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

26

1 reference

Europe PubMed Central

4 November 2017

12

1 reference

Europe PubMed Central

4 November 2017

1051-1070

1 reference

Europe PubMed Central

4 November 2017

https://scigraph.springernature.com/pub.10.1007/s40263-012-0013-2

0 references

Symptomatic and palliative care for stroke survivors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Motor recovery after stroke: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Natural history of cognitive impairment after stroke and factors associated with its recovery.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Cognitive impairment after stroke: clinical determinants and its associations with long-term stroke outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Progressive cognitive impairment after stroke.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Central post-stroke pain: clinical characteristics, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Stroke rehabilitation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Control of synaptic strength by glial TNFalpha

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

How TNF was recognized as a key mechanism of disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The cytokine theory of human cerebral malaria.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The blood-brain barrier: bottleneck in brain drug development

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The roles of TNF in brain dysfunction and disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Implications of gliotransmission for the pharmacotherapy of CNS disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Early elevation of serum tumor necrosis factor-α is associated with poor outcome in subarachnoid hemorrhage

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Systemic and central immunity in Alzheimer's disease: therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Therapeutic evaluation of etanercept in a model of traumatic brain injury

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Perispinal etanercept: potential as an Alzheimer therapeutic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Inflammation and anti-inflammatory strategies for Alzheimer's disease--a mini-review

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Post-ischemic inflammation in the brain

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Synaptic scaling mediated by glial TNF-alpha

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Intrathecal inflammation precedes development of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Tumor necrosis factor alters synaptic transmission in rat hippocampal slices

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Perispinal Etanercept for Treatment of Alzheimers Disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Glia: they make your memories stick!

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The tripartite synapse: roles for gliotransmission in health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Perispinal etanercept for neuroinflammatory disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Targeted etanercept for treatment-refractory pain due to bone metastasis: Two case reports

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Perispinal etanercept: a new therapeutic paradigm in neurology

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Anti-TNF therapy in the injured spinal cord

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The craniospinal venous system

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Immediate anti-tumor necrosis factor-alpha (etanercept) therapy enhances axonal regeneration after sciatic nerve crush

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Etanercept attenuates pain-related behavior following compression of the dorsal root ganglion in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Immunomodulatory effects of etanercept in an experimental model of spinal cord injury

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Effects of Etanercept and Minocycline in a rat model of spinal cord injury

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Stroke and the immune system: from pathophysiology to new therapeutic strategies

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Cognitive function, gait speed decline, and comorbidities: the health, aging and body composition study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Short test of semantic and phonological fluency: normal performance, validity and test-retest reliability

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Mini-Mental State Examination versus Montreal Cognitive Assessment: rapid assessment tools for cognitive and functional outcome after aneurysmal subarachnoid hemorrhage.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The causes and treatment of pseudobulbar affect in ischemic stroke

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Placebo effect studies are susceptible to response bias and to other types of biases

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Placebo interventions, placebo effects and clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

When are randomised trials unnecessary? Picking signal from noise

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Etanercept: efficacy and safety for approved indications

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The major role of clinicians in the discovery of off-label drug therapies

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

In defense of case reports and case series

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

RELIABILITY OF GAIT PERFORMANCE TESTS IN MEN AND WOMEN WITH HEMIPARESIS AFTER STROKE

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The montreal cognitive assessment: short cognitive evaluation in a large stroke trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Recovery after stroke

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

The hemiplegic arm after stroke: measurement and recovery

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Recovery after stroke--the first 3 months

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against 'accepted wisdom'.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Barry Marshall 2005 Nobel laureate in medicine and physiology.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

Natural History and Effects on 2-Year Outcomes of Urinary Incontinence After Stroke

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0013-2

21 January 2018

An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of hemiplegic shoulder pain following stroke

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The vertebral vein system. Caldwell lecture, 1956.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of cognitive impairment by the Montreal cognitive assessment in patients with aneurysmal subarachnoid haemorrhage: prevalence, risk factors and correlations with 3 month outcomes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF in cerebral malaria.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AMPA receptor trafficking in homeostatic synaptic plasticity: functional molecules and signaling cascades.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo interventions for all clinical conditions

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cerebrospinal venous system: anatomy, physiology, and clinical implications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Permeability of the blood-brain barrier to soluble cytokine receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stroke patients who regain urinary continence in the first week after acute first-ever stroke have better prognosis than patients with persistent lower urinary tract dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Post-stroke cognitive impairments

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factors blocking agents: analogies and differences

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Barry Marshall. A gutsy gulp changes medical science.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurological Impairment Among Survivors of Intracerebral Hemorrhage: The FAST Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

History of the vertebral venous plexus and the significant contributions of Breschet and Batson.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The value of drug repositioning in the current pharmaceutical market

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept: effectiveness and safety data of a retrospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient experiences of bladder problems following stroke.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Montreal Cognitive Assessment: validity and utility in a memory clinic setting.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Perispinal TNF-alpha inhibition for discogenic pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dysphagia in acute ischaemic stroke: severity, recovery and relationship to stroke subtype

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrathecal etanercept partially restores morphine's antinociception in morphine-tolerant rats via attenuation of the glutamatergic transmission

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-012-0013-2

1 reference

Europe PubMed Central

4 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42674268&oldid=1965201497"